TITLE

ORATORY MARKERS IN IBD: MAGIC, OR UNNECESSARY TOYS?

AUTHOR(S)
Vermeire, S.; Van Assche, G.; Rutgeerts, P.
PUB. DATE
March 2006
SOURCE
Gut;Mar2006, Vol. 55 Issue 3, p426
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Laboratory markers have been investigated in inflammatory bowel disease (IBD) for diagnostic and differential diagnostic purposes, for assessment of disease activity and risk of complications, for prediction of relapse, and for monitoring the effect of therapy. The introduction of biological therapies in IBD has renewed interest in inflammatory markers (especially C reactive protein (CRP)), given their potential to select responders to these treatments. Of all the laboratory markers, CRP is the most studied and has been shown to have the best overall performance. CRP is an objective marker of inflammation and correlates well with disease activity in Crohn's disease (CD). Increased CRP levels are associated with better response rates and normal CRP levels predict high placebo response rates in clinical trials with biologicals. However, despite the advantages of CRP over other markers, it is still far from ideal. Furthermore, CRP correlates less well with disease activity in patients with ulcerative colitis (UC) as compared with CD. Other laboratory markers, including erythrocyte sedimentation rate (ESR), leucocyte and platelet count, albumin, and α1 acid glycoprotein (orosomucoid), have been studied either less extensively in IBD or have proven to be less useful than CRP. Faecal markers seem promising and may be more specific in detecting gut inflammation in patients with established IBD. Promising results have been reported with the use of faecal calprotectin in CD as well as in UC. Recent data however suggest that the performance of the faecal calprotectin test is superior for UC than for CD. Taken together, laboratory markers are useful and should be part of the global management of our IBD patients. They are however not magic and until more data become available, the use of CRP and other laboratory markers should be seen as an additive tool to clinical observation and physical examination rather than a replacement.
ACCESSION #
20098100

 

Related Articles

  • Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome. MING-HUI CHANG; JEN-WEI CHOU; SHAN-MING CHEN; MING-CHANG TSAI; YU-SHU SUN; CHUN-CHE LIN; CHING-PIN LIN // Molecular Medicine Reports;2014, Vol. 10 Issue 1, p522 

    The present study aimed to investigate faecal calprotectin as a diagnostic marker to differentiate between patients with inflammatory bowel disease (IBD) and those with irritable bowel syndrome (IBS). A total of 20 healthy control subjects, 26 patients with IBS and 58 patients with IBD,...

  • Magnetic resonance imaging of the small bowel in children with idiopathic inflammatory bowel disease: evaluation of disease activity. Alexopoulou, Efthymia; Roma, Eleftheria; Loggitsi, Dimitra; Economopoulos, Nikos; Papakonstantinou, Olympia; Panagiotou, Ioanna; Pahoula, Ioanna; Kelekis, Nikolaos L. // Pediatric Radiology;Aug2009, Vol. 39 Issue 8, p791 

    Examinations using ionizing radiation are frequently used in the evaluation of disease activity in children affected by idiopathic inflammatory bowel disease (IBD). To develop an MR imaging protocol without the need for fluoroscopic insertion of an enteral tube and to assess the disease activity...

  • Evolving Endpoints in IBD Management. Stidham, Ryan W.; Waljee, Akbar K.; Higgins, Peter D. R. // Inflammatory Bowel Disease Monitor;Jul2009, Vol. 10 Issue 3, p84 

    Assessment of disease activity in IBD has classically relied upon indices of clinical symptoms, including the Crohn's Disease Activity Index and Mayo Index scoring systems. While improving quality of life in patients with Crohn's disease and ulcerative colitis remains a primary therapeutic goal,...

  • Measuring disease activity in Crohn's disease: what is currently available to the clinician. D'Incà, Renata; Caccaro, Roberta // Clinical & Experimental Gastroenterology;2014, Vol. 7, p151 

    Crohn's disease (CD) is a chronic inflammatory bowel disease characterized by a relapsing-remitting clinical behavior and dominated by intestinal inflammation. Being a chronic disorder that with time develops into a disabling disease, it is important to monitor the severity of inflammation to...

  • MESENTERIC FAT IN CROHN'S DISEASE: A PATHOGENETIC HALLMARK OR AN INNOCENT BYSTANDER? Peyrin-Biroulet, Laurent; Chamaillard, Mathias; Gonzalez, Florent; Beclin, Elodie; Decourcelle, Cecilia; Antunes, Laurent; Gay, Jérôme; Neut, Christel; Colombel, Jean-Frédéric; Desreumaux, Pierre // Gut;Apr2007, Vol. 56 Issue 4, p577 

    The article discusses the normal and pathophysiological functions of mesenteric white adipose tissue (WAT). WAT may play an important role in the inflammatory and fibrotic processes in Crohn's disease, a frequent and complex form of inflammatory bowel disease. The mesenteric fat may contribute...

  • Prevalence and influences of hepatitis B virus infection on inflammatory bowel disease: a retrospective study in southern China. Yao He; Pingping Xu; Yujun Chen; Rongping Yang; Baili Chen; Zhirong Zeng; Minhu Chen // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 5, p8078 

    The prevalence of Hepatitis B Virus (HBV) infection in inflammatory bowel disease (IBD) has been reported differently across the world. The present study retrospectively included 675 consecutive IBD patients (449 Crohn's disease, CD and 226 ulcerative colitis, UC) from July 2006 to July 2012....

  • Efficacy of T2 in Active Crohn’s Disease: A Prospective Study Report. Qingsong Tao; Xinbo Wang; Zhiming Wang; Jieshou Li // Digestive Diseases & Sciences;Aug2007, Vol. 52 Issue 8, p1790 

    Abstract  To date few therapies have been shown to reliably prevent the evolution of Crohn’s disease (CD). The traditional Chinese medicine, Tripterygium wilfordii Hook F (TWHF), has both immunomodulatory and anti-inflammatory activities. Our aim was to investigate...

  • Certolizumab Pegol: In Crohn's Disease.  // BioDrugs;2007, Vol. 21 Issue 3, p195 

    â–´ Certolizumab pegol is a pegylated humanized Fab' fragment of an anti-tumor necrosis factor-a (TNFa) monoclonal antibody, which binds with high affinity to both membrane-bound and soluble TNFa and demonstrates high neutralizing potency for these factors. â–´ The elimination half-life...

  • Subclinical Intestinal Inflammation in Patients with Crohn's Disease Following Bowel Resection: A Smoldering Fire. Ruffolo, Cesare; Scarpa, Marco; Faggian, Diego; Basso, Daniela; D'Incà, Renata; Plebani, Mario; Sturniolo, Giacomo C.; Bassi, Nicolò; Angriman, Imerio // Journal of Gastrointestinal Surgery;Jan2010, Vol. 14 Issue 1, p24 

    Background/Aims Fecal lactoferrin is the direct expression of intestinal inflammation in Crohn's disease (CD). The aim of this study was to analyze the in vivo intimate correlation between intestinal and systemic inflammation in CD patients in clinical remission following bowel resection. The...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics